Council and audience questions pressed panelists on how to define a 'healthy' microbiome, steps to standardize direct-to-consumer tests, the regulation of probiotics and microbiome products, and how to incentivize producers to reduce antibiotic reliance.

Health professionals who take six months of maternity or carer’s leave will get a 30% discount on their registration fees, starting July 2025.

During the hearing dozens of residents spoke for two minutes each. Many chronic‑pain patients and people in recovery urged the council to preserve access to natural leaf kratom with regulation; several relatives of people who died urged a full ban on all kratom products.

The subcommittee cautioned that commercial microbiome testing and many probiotics lack evidence and highlighted regulatory gaps for live biotherapeutics; speakers urged clearer frameworks and safety-focused approval pathways.

Planning staff showed a draft buffer map and commissioners debated whether to use 500- or 1,000-foot separations from schools, parks and between businesses; staff will return with ordinance language, a 1,000-foot alternative map and a property list for review.

Department of Health officials told the Joint Government Operations Committee on Feb. 19 that multiple health-related licensing boards ran deficits in 2023–25 and are pursuing fee changes and system upgrades; legal staff and lawmakers debated why agencies use two- to three-year projections and noted past statutory sweeps of reserve funds.

The Rensselaer County Legislature passed a local law prohibiting the sale and distribution of kratom after public testimony and council debate; an amendment to add a sunset clause failed and the measure passed on a roll call vote, 15–2.

Counsel described a case in which a convenience store allegedly sold legend drugs and unlicensed high-THC cannabis products; the proposed resolution would surrender a nonlegend drug permit and impose a $1,000 payment — a penalty some commissioners called insufficient given allegations of diversion and criminal activity.

At first reading, the board introduced an ordinance to regulate certain kratom products — targeting synthetic or enhanced high‑potency formulations, restricting sales to 21+, imposing labeling and point‑of‑sale controls, and establishing a 500‑foot buffer from schools and similar locations; enforcement will start with education and graduated penalties.

This in-depth consideration of the determinants of Indigenous governance in an organisation is relevant for hospital and health service boards, Primary Health Networks, university faculties, research institutes, regulators and government departments.

This in-depth consideration of the determinants of Indigenous governance in an organisation is relevant for hospital and health service boards, Primary Health Networks, university faculties, research institutes, regulators and government departments.

OLA recommended MDH meet statutory inspection timelines and urged DHS to revise its assisted‑living report card to incorporate substantiated maltreatment findings and licensing sanctions after finding some poorly rated facilities had serious substantiated incidents.

Kootenai County Coroner Dr. Johnson told the Post Falls City Council kratom has appeared in multiple local autopsies and urged action; council directed staff to research enforceability, testing options, and public outreach before deciding whether to pursue a local ban.

SB 1303 would extend the California Board of Naturopathic Medicine through 2031, remove recent scope‑of‑practice language, and add title‑protection and transparency measures. Board officials told the committee most complaints involve unlicensed practice and said amendments are consumer‑focused.

Committee directed staff to finalize ordinance language creating a city license for vape/smoke retailers (including existing carryouts selling vape products), discussed a fee to cover police inspections (a $5,000 example was raised), and set a minimum of four unannounced inspections per year.

The Therapeutic Goods Administration (TGA) has reviewed the use of artificial intelligence-powered clinical scribes, and plans to begin compliance action against some suppliers, but some experts believe tougher regulatory action is needed.

The Therapeutic Goods Administration (TGA) has reviewed the use of artificial intelligence-powered clinical scribes, and plans to begin compliance action against some suppliers, but some experts believe tougher regulatory action is needed.

Alcohol Law Enforcement demonstrated grant‑funded field analyzers and reported that the devices flagged most samples as above delta‑9 thresholds; licensed confirmatory lab testing corroborated a high percentage of positive results.

The U.S. Food and Drug Administration (FDA) advisory panel has voted against approving Capricor's therapy for a specific medical condition, raising concerns about its efficacy and safety. The decision comes after extensive review of clinical trial data, with panel members citing insufficient evidence to support the treatment's benefits. Capricor, a biotechnology company, had sought approval for its therapy targeting a rare genetic disorder, but the panel found the studies lacked statistical significance and long-term patient outcomes. This rejection highlights the rigorous standards required for drug approvals and underscores the importance of robust clinical data in medical decision-making. The FDA may reconsider its stance if additional research or updated trial results are submitted, but for now, the therapy remains under scrutiny. Critics argue that the panel's decision could impact patients awaiting potential treatment options, while proponents emphasize the need to prioritize patient safety over expedited approvals. This case exemplifies the complex balance between innovation and regulatory oversight in healthcare.

The interim joint committee on health services approved a committee amendment to an emergency optometry regulation removing one alternate exam pathway and directing the Kentucky Board of Optometric Examiners to require standard National Board of Examiners in Optometry (NBEO) parts for exams taken after 07/17/2026, following an attorney general opinion about regulatory process.